Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| uniQure N.V.QURE · Entity 4162 | Chief Commercial Officer | January 26, 2018 | January 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
uniQure N.V.
Report date January 26, 2018 · Filed January 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 93,817 |
Reported balance
After 2018-01-26 transaction · row 1
1 source rowRow 1 · 2018-01-26 · Grant · Acquired 8,566 · Balance 93,817 F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.39 · Expires 2028-01-26 | Direct | 22,843 |
Reported balance
After 2018-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-26 · Grant · Acquired 22,843 · Balance 22,843 F2: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates.
F2: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date January 28, 2020 · Filed January 29, 2020
Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2028-09-11 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-28 · Disposition to issuer · Disposed 400,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-28 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2020 Filed Jan 29, 2020 16:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 200,000 | Not disclosed Strike: $2.18 | Not disclosed |
DisclosureSEC source: 0001562180-20-000669 · primarydocument.xml · derivative · entry 2 Firuta Paul E · CIK 0001602727 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 400,000 | Not disclosed Strike: $3.32 | Not disclosed |
DisclosureSEC source: 0001562180-20-000669 · primarydocument.xml · derivative · entry 1 Firuta Paul E · CIK 0001602727 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2028-09-11 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:47 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-19-005365 · doc4.xml · derivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| September 11, 2018 Filed Sep 12, 2018 17:57 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 400,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001209191-18-050688 · doc4.xml · derivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2028-09-11 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 16:31 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 22,843 | $0.00 Strike: $19.39 | $0.00 |
DisclosureSEC source: 0000904454-18-000070 · edgar.xml · derivative · entry 2 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,843 Underlying: Ordinary Shares · 22,843 shares Expires 2028-01-26 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 16:31 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000070 · edgar.xml · nonDerivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,817 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 03, 2018 Filed Jan 3, 2018 22:50 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 5,864 | $20.13 | $118,028.25 |
DisclosureSEC source: 0001209191-18-001200 · doc4.xml · nonDerivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,251 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the reporting person sold the ordinary shares and remitted the proceeds therefrom to the issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.66 to $20.47, inclusive. The reporting person undertakes to provide uniQure N.V., any security holder of uniQure N.V. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price ranges set forth in this footnote. F3 · balance_after: Consists of (i) 11,636 ordinary shares, (ii) 56,115 performance share units that vest in full on January 27, 2020 and (iii) 17,500 restricted stock units previously disclosed by the reporting person on Table II, that vest in full on December 31, 2018. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:34 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 56,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065946 · doc4.xml · nonDerivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,115 F1 · date: On January 27, 2017, the uniQure Board of Directors approved a grant to Mr. Firuta of 43,500 performance share units linked to the achievement of specified performance goals in 2017. On December 13, 2017, the Board of Directors determined that certain performance goals were met. Following the Board's determination, each performance share unit represents the right to receive one ordinary share, and will vest in full on January 27, 2020. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:23 UTC | uniQure N.V. QURE · Entity 4162 | GrantPreformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003717 · doc1.xml · derivative · entry 2 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:23 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003717 · doc1.xml · derivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 22:04 UTC Amendment | uniQure N.V. QURE · Entity 4162 | GrantPreformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008376 · doc1.xml · derivative · entry 2 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 22:04 UTC Amendment | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008376 · doc1.xml · derivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.